Humana (HUM) intends to reaffirm its guidance
Tweet
Share
E-mail
Get Alerts HUM Hot Sheet
Price: $382.04 +1.06%
Financial Fact:
Provision for income taxes: 452M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Provision for income taxes: 452M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Humana (NYSE: HUM)
Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between September 3, 2024 and September 30, 2024. During these conferences and meetings, the Company intends to reaffirm its guidance of approximately $12.81 in diluted earnings per common share (“EPS”) or approximately $16.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2024 (“FY 2024”). This guidance is consistent with the guidance issued in Humana’s press release dated July 31, 2024. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company’s website at www.humana.com.
The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company’s core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:
| Diluted earnings per common share | FY 2024 Guidance | ||||
| GAAP | approximately $12.81 | ||||
| Amortization of identifiable intangibles | 0.50 | ||||
| Put/call valuation adjustments associated with Company's non-consolidating minority interest investments | 1.65 | ||||
| Impact of exit of employer group commercial medical products business | 1.21 | ||||
| Value creation initiatives | 0.80 | ||||
| Cumulative net tax impact of non-GAAP adjustments | (0.97) | ||||
| Adjusted (non-GAAP) – FY 2024 projected | approximately $16.00 | ||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deere conference call: 2027 orders up mid-single digits from last year)
- Richardson Electronics to deliver 18 battery storage systems in Alaska
- Bessent on Iran: maximum economic pressure means likely not a kinetic restart
Create E-mail Alert Related Categories
8K, Corporate News, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
